Tecentriq beats rivals to EU breast cancer marketRoche has claimed approval in Europe for Tecentriq as a therapy for hard-to-treat triple-negative breast cancer (TNBC), ahead Share XTecentriq beats rivals to EU breast cancer markethttps://pharmaphorum.com/news/tecentriq-beats-rivals-to-eu-breast-cancer-market/
Study resurrects Merck’s hopes for Keytruda in breast cancerJust a few weeks ago Merck & Co was lamenting a failed trial for Keytruda in triple-negative breast Share XStudy resurrects Merck’s hopes for Keytruda in breast cancerhttps://pharmaphorum.com/news/study-resurrects-mercks-hopes-for-keytruda-in-breast-cancer/
Merck & Co’s Keytruda fails in triple negative breast cancer trialMost of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of Share XMerck & Co’s Keytruda fails in triple negative breast cancer trialhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-triple-negative-breast-cancer-trial/
BMS and Infinity aim to overcome triple negative breast cancer resistance to IOBMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy Share XBMS and Infinity aim to overcome triple negative breast cancer resistance to IOhttps://pharmaphorum.com/news/bms-infinity-aim-overcome-triple-negative-breast-cancer-resistance-io/
